nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapagliflozin—CYP2A6—prostate cancer	0.138	0.466	CbGaD
Dapagliflozin—CYP1A1—prostate cancer	0.097	0.326	CbGaD
Dapagliflozin—CYP3A4—prostate cancer	0.0619	0.208	CbGaD
Dapagliflozin—CYP1A1—Flutamide—prostate cancer	0.0334	0.0866	CbGbCtD
Dapagliflozin—UGT2B7—Epirubicin—prostate cancer	0.0265	0.0687	CbGbCtD
Dapagliflozin—CYP1A1—Estrone—prostate cancer	0.0242	0.0626	CbGbCtD
Dapagliflozin—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.018	0.0466	CbGbCtD
Dapagliflozin—CYP2C9—Bicalutamide—prostate cancer	0.0162	0.0421	CbGbCtD
Dapagliflozin—CYP2C9—Nilutamide—prostate cancer	0.0162	0.0421	CbGbCtD
Dapagliflozin—CYP1A2—Flutamide—prostate cancer	0.0149	0.0387	CbGbCtD
Dapagliflozin—CYP2D6—Bicalutamide—prostate cancer	0.0149	0.0385	CbGbCtD
Dapagliflozin—ABCB1—Estramustine—prostate cancer	0.0147	0.038	CbGbCtD
Dapagliflozin—SLC5A4—urine—prostate cancer	0.0139	0.25	CbGeAlD
Dapagliflozin—CYP1A1—Estradiol—prostate cancer	0.0139	0.036	CbGbCtD
Dapagliflozin—CYP2D6—Abiraterone—prostate cancer	0.0123	0.0319	CbGbCtD
Dapagliflozin—CYP1A2—Estrone—prostate cancer	0.0108	0.028	CbGbCtD
Dapagliflozin—SLC5A2—urine—prostate cancer	0.0105	0.19	CbGeAlD
Dapagliflozin—CYP2C9—Estrone—prostate cancer	0.00973	0.0252	CbGbCtD
Dapagliflozin—ABCB1—Cabazitaxel—prostate cancer	0.00966	0.025	CbGbCtD
Dapagliflozin—CYP3A4—Bicalutamide—prostate cancer	0.00944	0.0245	CbGbCtD
Dapagliflozin—ABCB1—Estrone—prostate cancer	0.00944	0.0245	CbGbCtD
Dapagliflozin—CYP3A4—Estramustine—prostate cancer	0.00878	0.0227	CbGbCtD
Dapagliflozin—ABCB1—Ethinyl Estradiol—prostate cancer	0.00842	0.0218	CbGbCtD
Dapagliflozin—CYP3A4—Flutamide—prostate cancer	0.00783	0.0203	CbGbCtD
Dapagliflozin—CYP3A4—Abiraterone—prostate cancer	0.00783	0.0203	CbGbCtD
Dapagliflozin—CYP2C9—Capecitabine—prostate cancer	0.00737	0.0191	CbGbCtD
Dapagliflozin—CYP1A2—Conjugated Estrogens—prostate cancer	0.00706	0.0183	CbGbCtD
Dapagliflozin—CYP1A2—Estradiol—prostate cancer	0.0062	0.0161	CbGbCtD
Dapagliflozin—ABCB1—Conjugated Estrogens—prostate cancer	0.00618	0.016	CbGbCtD
Dapagliflozin—CYP3A4—Cabazitaxel—prostate cancer	0.00579	0.015	CbGbCtD
Dapagliflozin—CYP3A4—Estrone—prostate cancer	0.00566	0.0147	CbGbCtD
Dapagliflozin—ABCB1—Mitoxantrone—prostate cancer	0.00562	0.0145	CbGbCtD
Dapagliflozin—CYP2C9—Estradiol—prostate cancer	0.00559	0.0145	CbGbCtD
Dapagliflozin—ABCB1—Estradiol—prostate cancer	0.00542	0.0141	CbGbCtD
Dapagliflozin—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00504	0.0131	CbGbCtD
Dapagliflozin—ABCB1—Prednisone—prostate cancer	0.00466	0.0121	CbGbCtD
Dapagliflozin—CYP1A2—Etoposide—prostate cancer	0.00405	0.0105	CbGbCtD
Dapagliflozin—CYP3A4—Conjugated Estrogens—prostate cancer	0.0037	0.00959	CbGbCtD
Dapagliflozin—ABCB1—Etoposide—prostate cancer	0.00354	0.00917	CbGbCtD
Dapagliflozin—SLC5A4—renal system—prostate cancer	0.0034	0.0613	CbGeAlD
Dapagliflozin—CYP3A4—Mitoxantrone—prostate cancer	0.00336	0.00872	CbGbCtD
Dapagliflozin—CYP3A4—Estradiol—prostate cancer	0.00325	0.00842	CbGbCtD
Dapagliflozin—ABCB1—Docetaxel—prostate cancer	0.00324	0.00839	CbGbCtD
Dapagliflozin—SLC5A1—prostate gland—prostate cancer	0.00287	0.0516	CbGeAlD
Dapagliflozin—CYP3A4—Prednisone—prostate cancer	0.00279	0.00724	CbGbCtD
Dapagliflozin—SLC5A2—renal system—prostate cancer	0.00258	0.0464	CbGeAlD
Dapagliflozin—ABCB1—Doxorubicin—prostate cancer	0.00242	0.00626	CbGbCtD
Dapagliflozin—CYP2D6—Doxorubicin—prostate cancer	0.00228	0.0059	CbGbCtD
Dapagliflozin—CYP3A4—Etoposide—prostate cancer	0.00212	0.0055	CbGbCtD
Dapagliflozin—SLC5A1—epithelium—prostate cancer	0.00211	0.0379	CbGeAlD
Dapagliflozin—SLC5A1—renal system—prostate cancer	0.00195	0.0352	CbGeAlD
Dapagliflozin—CYP3A4—Docetaxel—prostate cancer	0.00194	0.00503	CbGbCtD
Dapagliflozin—SLC5A2—testis—prostate cancer	0.00167	0.03	CbGeAlD
Dapagliflozin—CYP1A2—urine—prostate cancer	0.00152	0.0275	CbGeAlD
Dapagliflozin—UGT2B7—prostate gland—prostate cancer	0.00145	0.0262	CbGeAlD
Dapagliflozin—CYP2C9—urine—prostate cancer	0.00145	0.0261	CbGeAlD
Dapagliflozin—CYP3A4—Doxorubicin—prostate cancer	0.00145	0.00375	CbGbCtD
Dapagliflozin—SLC5A1—testis—prostate cancer	0.00126	0.0227	CbGeAlD
Dapagliflozin—UGT1A9—renal system—prostate cancer	0.00123	0.0221	CbGeAlD
Dapagliflozin—CYP3A4—urine—prostate cancer	0.0011	0.0199	CbGeAlD
Dapagliflozin—CYP2D6—urine—prostate cancer	0.00109	0.0196	CbGeAlD
Dapagliflozin—CYP2A6—prostate gland—prostate cancer	0.00104	0.0188	CbGeAlD
Dapagliflozin—UGT2B7—renal system—prostate cancer	0.000991	0.0179	CbGeAlD
Dapagliflozin—CYP2A6—seminal vesicle—prostate cancer	0.000881	0.0159	CbGeAlD
Dapagliflozin—UGT2B7—testis—prostate cancer	0.000641	0.0115	CbGeAlD
Dapagliflozin—Canagliflozin—CYP3A4—prostate cancer	0.00055	1	CrCbGaD
Dapagliflozin—CYP1A1—epithelium—prostate cancer	0.000397	0.00715	CbGeAlD
Dapagliflozin—CYP1A2—renal system—prostate cancer	0.000373	0.00672	CbGeAlD
Dapagliflozin—CYP1A1—renal system—prostate cancer	0.000368	0.00663	CbGeAlD
Dapagliflozin—CYP1A1—urethra—prostate cancer	0.000361	0.00651	CbGeAlD
Dapagliflozin—ABCB1—prostate gland—prostate cancer	0.00028	0.00505	CbGeAlD
Dapagliflozin—CYP3A4—renal system—prostate cancer	0.00027	0.00487	CbGeAlD
Dapagliflozin—CYP2D6—renal system—prostate cancer	0.000266	0.00479	CbGeAlD
Dapagliflozin—ABCB1—seminal vesicle—prostate cancer	0.000237	0.00427	CbGeAlD
Dapagliflozin—ABCB1—epithelium—prostate cancer	0.000206	0.00371	CbGeAlD
Dapagliflozin—ABCB1—renal system—prostate cancer	0.000191	0.00344	CbGeAlD
Dapagliflozin—ABCB1—urethra—prostate cancer	0.000188	0.00338	CbGeAlD
Dapagliflozin—CYP1A1—lymph node—prostate cancer	0.000172	0.00311	CbGeAlD
Dapagliflozin—CYP2D6—testis—prostate cancer	0.000172	0.00309	CbGeAlD
Dapagliflozin—ABCB1—bone marrow—prostate cancer	0.000145	0.0026	CbGeAlD
Dapagliflozin—ABCB1—testis—prostate cancer	0.000124	0.00223	CbGeAlD
Dapagliflozin—Back pain—Mitoxantrone—prostate cancer	9.72e-05	0.000744	CcSEcCtD
Dapagliflozin—Angina pectoris—Docetaxel—prostate cancer	9.71e-05	0.000743	CcSEcCtD
Dapagliflozin—Neoplasm—Epirubicin—prostate cancer	9.69e-05	0.000742	CcSEcCtD
Dapagliflozin—Influenza—Capecitabine—prostate cancer	9.65e-05	0.000739	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Conjugated Estrogens—prostate cancer	9.49e-05	0.000727	CcSEcCtD
Dapagliflozin—Constipation—Goserelin—prostate cancer	9.49e-05	0.000727	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Etoposide—prostate cancer	9.48e-05	0.000726	CcSEcCtD
Dapagliflozin—Nausea—Bicalutamide—prostate cancer	9.48e-05	0.000726	CcSEcCtD
Dapagliflozin—Urethral disorder—Etoposide—prostate cancer	9.41e-05	0.00072	CcSEcCtD
Dapagliflozin—Constipation—Conjugated Estrogens—prostate cancer	9.4e-05	0.00072	CcSEcCtD
Dapagliflozin—Angina pectoris—Capecitabine—prostate cancer	9.4e-05	0.00072	CcSEcCtD
Dapagliflozin—Blood urea increased—Doxorubicin—prostate cancer	9.36e-05	0.000716	CcSEcCtD
Dapagliflozin—Vaginal infection—Doxorubicin—prostate cancer	9.36e-05	0.000716	CcSEcCtD
Dapagliflozin—Hypertension—Estradiol—prostate cancer	9.31e-05	0.000713	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Estradiol—prostate cancer	9.12e-05	0.000698	CcSEcCtD
Dapagliflozin—Discomfort—Estradiol—prostate cancer	9.07e-05	0.000694	CcSEcCtD
Dapagliflozin—Phlebitis—Epirubicin—prostate cancer	9.03e-05	0.000691	CcSEcCtD
Dapagliflozin—Dysuria—Capecitabine—prostate cancer	9.02e-05	0.000691	CcSEcCtD
Dapagliflozin—Neoplasm—Doxorubicin—prostate cancer	8.96e-05	0.000686	CcSEcCtD
Dapagliflozin—ABCB1—lymph node—prostate cancer	8.96e-05	0.00161	CbGeAlD
Dapagliflozin—Diabetes mellitus—Epirubicin—prostate cancer	8.94e-05	0.000685	CcSEcCtD
Dapagliflozin—Dizziness—Ethinyl Estradiol—prostate cancer	8.92e-05	0.000683	CcSEcCtD
Dapagliflozin—Infestation NOS—Docetaxel—prostate cancer	8.89e-05	0.00068	CcSEcCtD
Dapagliflozin—Infestation—Docetaxel—prostate cancer	8.89e-05	0.00068	CcSEcCtD
Dapagliflozin—Urticaria—Goserelin—prostate cancer	8.82e-05	0.000675	CcSEcCtD
Dapagliflozin—Oedema—Estradiol—prostate cancer	8.8e-05	0.000674	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Estradiol—prostate cancer	8.8e-05	0.000674	CcSEcCtD
Dapagliflozin—Body temperature increased—Goserelin—prostate cancer	8.77e-05	0.000672	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Docetaxel—prostate cancer	8.76e-05	0.000671	CcSEcCtD
Dapagliflozin—Infection—Estradiol—prostate cancer	8.74e-05	0.000669	CcSEcCtD
Dapagliflozin—Renal failure—Docetaxel—prostate cancer	8.74e-05	0.000669	CcSEcCtD
Dapagliflozin—Urticaria—Conjugated Estrogens—prostate cancer	8.73e-05	0.000669	CcSEcCtD
Dapagliflozin—Myocardial infarction—Docetaxel—prostate cancer	8.71e-05	0.000667	CcSEcCtD
Dapagliflozin—Body temperature increased—Conjugated Estrogens—prostate cancer	8.69e-05	0.000665	CcSEcCtD
Dapagliflozin—Hypertension—Mitoxantrone—prostate cancer	8.67e-05	0.000664	CcSEcCtD
Dapagliflozin—Infestation NOS—Capecitabine—prostate cancer	8.6e-05	0.000659	CcSEcCtD
Dapagliflozin—Infestation—Capecitabine—prostate cancer	8.6e-05	0.000659	CcSEcCtD
Dapagliflozin—Skin disorder—Estradiol—prostate cancer	8.55e-05	0.000654	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Estradiol—prostate cancer	8.51e-05	0.000651	CcSEcCtD
Dapagliflozin—Rash—Ethinyl Estradiol—prostate cancer	8.5e-05	0.000651	CcSEcCtD
Dapagliflozin—Dermatitis—Ethinyl Estradiol—prostate cancer	8.5e-05	0.00065	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Capecitabine—prostate cancer	8.48e-05	0.000649	CcSEcCtD
Dapagliflozin—Renal failure—Capecitabine—prostate cancer	8.46e-05	0.000647	CcSEcCtD
Dapagliflozin—Discomfort—Mitoxantrone—prostate cancer	8.45e-05	0.000647	CcSEcCtD
Dapagliflozin—Headache—Ethinyl Estradiol—prostate cancer	8.45e-05	0.000647	CcSEcCtD
Dapagliflozin—Myocardial infarction—Capecitabine—prostate cancer	8.43e-05	0.000646	CcSEcCtD
Dapagliflozin—Urinary tract infection—Capecitabine—prostate cancer	8.36e-05	0.00064	CcSEcCtD
Dapagliflozin—Phlebitis—Doxorubicin—prostate cancer	8.35e-05	0.000639	CcSEcCtD
Dapagliflozin—Diabetes mellitus—Doxorubicin—prostate cancer	8.27e-05	0.000633	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Mitoxantrone—prostate cancer	8.2e-05	0.000628	CcSEcCtD
Dapagliflozin—Oedema—Mitoxantrone—prostate cancer	8.2e-05	0.000628	CcSEcCtD
Dapagliflozin—Hypersensitivity—Goserelin—prostate cancer	8.18e-05	0.000626	CcSEcCtD
Dapagliflozin—Infection—Mitoxantrone—prostate cancer	8.14e-05	0.000624	CcSEcCtD
Dapagliflozin—Hypersensitivity—Conjugated Estrogens—prostate cancer	8.1e-05	0.00062	CcSEcCtD
Dapagliflozin—Back pain—Etoposide—prostate cancer	8.08e-05	0.000619	CcSEcCtD
Dapagliflozin—Nausea—Ethinyl Estradiol—prostate cancer	8.01e-05	0.000613	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Epirubicin—prostate cancer	7.97e-05	0.00061	CcSEcCtD
Dapagliflozin—Skin disorder—Mitoxantrone—prostate cancer	7.96e-05	0.00061	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Epirubicin—prostate cancer	7.94e-05	0.000608	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Mitoxantrone—prostate cancer	7.93e-05	0.000607	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Docetaxel—prostate cancer	7.88e-05	0.000603	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Docetaxel—prostate cancer	7.84e-05	0.0006	CcSEcCtD
Dapagliflozin—Urethral disorder—Docetaxel—prostate cancer	7.82e-05	0.000599	CcSEcCtD
Dapagliflozin—Hyponatraemia—Epirubicin—prostate cancer	7.81e-05	0.000598	CcSEcCtD
Dapagliflozin—Pain in extremity—Epirubicin—prostate cancer	7.78e-05	0.000595	CcSEcCtD
Dapagliflozin—Hypotension—Mitoxantrone—prostate cancer	7.66e-05	0.000586	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Capecitabine—prostate cancer	7.63e-05	0.000584	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Estradiol—prostate cancer	7.6e-05	0.000582	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Capecitabine—prostate cancer	7.59e-05	0.000581	CcSEcCtD
Dapagliflozin—Urethral disorder—Capecitabine—prostate cancer	7.57e-05	0.00058	CcSEcCtD
Dapagliflozin—Acute coronary syndrome—Prednisone—prostate cancer	7.55e-05	0.000578	CcSEcCtD
Dapagliflozin—Constipation—Estradiol—prostate cancer	7.52e-05	0.000576	CcSEcCtD
Dapagliflozin—Myocardial infarction—Prednisone—prostate cancer	7.51e-05	0.000575	CcSEcCtD
Dapagliflozin—Hypoglycaemia—Doxorubicin—prostate cancer	7.37e-05	0.000564	CcSEcCtD
Dapagliflozin—Cerebrovascular accident—Doxorubicin—prostate cancer	7.34e-05	0.000562	CcSEcCtD
Dapagliflozin—Dizziness—Goserelin—prostate cancer	7.34e-05	0.000562	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Epirubicin—prostate cancer	7.29e-05	0.000558	CcSEcCtD
Dapagliflozin—Dizziness—Conjugated Estrogens—prostate cancer	7.27e-05	0.000557	CcSEcCtD
Dapagliflozin—Dehydration—Epirubicin—prostate cancer	7.23e-05	0.000554	CcSEcCtD
Dapagliflozin—Hyponatraemia—Doxorubicin—prostate cancer	7.23e-05	0.000553	CcSEcCtD
Dapagliflozin—Hypertension—Etoposide—prostate cancer	7.21e-05	0.000552	CcSEcCtD
Dapagliflozin—Pain in extremity—Doxorubicin—prostate cancer	7.2e-05	0.000551	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Epirubicin—prostate cancer	7.1e-05	0.000544	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	7.06e-05	0.000541	CcSEcCtD
Dapagliflozin—Discomfort—Etoposide—prostate cancer	7.03e-05	0.000538	CcSEcCtD
Dapagliflozin—Constipation—Mitoxantrone—prostate cancer	7.01e-05	0.000537	CcSEcCtD
Dapagliflozin—Rash—Goserelin—prostate cancer	7e-05	0.000536	CcSEcCtD
Dapagliflozin—Dermatitis—Goserelin—prostate cancer	6.99e-05	0.000535	CcSEcCtD
Dapagliflozin—Urticaria—Estradiol—prostate cancer	6.99e-05	0.000535	CcSEcCtD
Dapagliflozin—Body temperature increased—Estradiol—prostate cancer	6.96e-05	0.000532	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Epirubicin—prostate cancer	6.95e-05	0.000532	CcSEcCtD
Dapagliflozin—Headache—Goserelin—prostate cancer	6.95e-05	0.000532	CcSEcCtD
Dapagliflozin—Malnutrition—Docetaxel—prostate cancer	6.94e-05	0.000532	CcSEcCtD
Dapagliflozin—Rash—Conjugated Estrogens—prostate cancer	6.93e-05	0.000531	CcSEcCtD
Dapagliflozin—Dermatitis—Conjugated Estrogens—prostate cancer	6.93e-05	0.00053	CcSEcCtD
Dapagliflozin—Headache—Conjugated Estrogens—prostate cancer	6.89e-05	0.000527	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Etoposide—prostate cancer	6.82e-05	0.000522	CcSEcCtD
Dapagliflozin—Infection—Etoposide—prostate cancer	6.77e-05	0.000519	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Prednisone—prostate cancer	6.76e-05	0.000518	CcSEcCtD
Dapagliflozin—Blood creatinine increased—Doxorubicin—prostate cancer	6.74e-05	0.000516	CcSEcCtD
Dapagliflozin—Malnutrition—Capecitabine—prostate cancer	6.72e-05	0.000515	CcSEcCtD
Dapagliflozin—Influenza—Epirubicin—prostate cancer	6.72e-05	0.000515	CcSEcCtD
Dapagliflozin—Back pain—Docetaxel—prostate cancer	6.72e-05	0.000514	CcSEcCtD
Dapagliflozin—Dehydration—Doxorubicin—prostate cancer	6.69e-05	0.000512	CcSEcCtD
Dapagliflozin—Skin disorder—Etoposide—prostate cancer	6.62e-05	0.000507	CcSEcCtD
Dapagliflozin—Nausea—Goserelin—prostate cancer	6.59e-05	0.000505	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Etoposide—prostate cancer	6.59e-05	0.000505	CcSEcCtD
Dapagliflozin—Orthostatic hypotension—Doxorubicin—prostate cancer	6.57e-05	0.000503	CcSEcCtD
Dapagliflozin—Angina pectoris—Epirubicin—prostate cancer	6.55e-05	0.000501	CcSEcCtD
Dapagliflozin—Nausea—Conjugated Estrogens—prostate cancer	6.53e-05	0.0005	CcSEcCtD
Dapagliflozin—Urticaria—Mitoxantrone—prostate cancer	6.51e-05	0.000499	CcSEcCtD
Dapagliflozin—Back pain—Capecitabine—prostate cancer	6.5e-05	0.000498	CcSEcCtD
Dapagliflozin—Hypersensitivity—Estradiol—prostate cancer	6.48e-05	0.000496	CcSEcCtD
Dapagliflozin—Body temperature increased—Mitoxantrone—prostate cancer	6.48e-05	0.000496	CcSEcCtD
Dapagliflozin—Nasopharyngitis—Doxorubicin—prostate cancer	6.44e-05	0.000493	CcSEcCtD
Dapagliflozin—Hypotension—Etoposide—prostate cancer	6.37e-05	0.000488	CcSEcCtD
Dapagliflozin—Dysuria—Epirubicin—prostate cancer	6.29e-05	0.000481	CcSEcCtD
Dapagliflozin—Influenza—Doxorubicin—prostate cancer	6.22e-05	0.000476	CcSEcCtD
Dapagliflozin—Pollakiuria—Epirubicin—prostate cancer	6.21e-05	0.000475	CcSEcCtD
Dapagliflozin—Angina pectoris—Doxorubicin—prostate cancer	6.06e-05	0.000464	CcSEcCtD
Dapagliflozin—Hypersensitivity—Mitoxantrone—prostate cancer	6.04e-05	0.000462	CcSEcCtD
Dapagliflozin—Hypertension—Docetaxel—prostate cancer	6e-05	0.000459	CcSEcCtD
Dapagliflozin—Infestation NOS—Epirubicin—prostate cancer	5.99e-05	0.000459	CcSEcCtD
Dapagliflozin—Infestation—Epirubicin—prostate cancer	5.99e-05	0.000459	CcSEcCtD
Dapagliflozin—Malnutrition—Prednisone—prostate cancer	5.99e-05	0.000458	CcSEcCtD
Dapagliflozin—Renal failure—Epirubicin—prostate cancer	5.89e-05	0.000451	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Etoposide—prostate cancer	5.89e-05	0.000451	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	5.87e-05	0.000449	CcSEcCtD
Dapagliflozin—Constipation—Etoposide—prostate cancer	5.83e-05	0.000446	CcSEcCtD
Dapagliflozin—Urinary tract infection—Epirubicin—prostate cancer	5.83e-05	0.000446	CcSEcCtD
Dapagliflozin—Dizziness—Estradiol—prostate cancer	5.82e-05	0.000445	CcSEcCtD
Dapagliflozin—Dysuria—Doxorubicin—prostate cancer	5.82e-05	0.000445	CcSEcCtD
Dapagliflozin—Hypertension—Capecitabine—prostate cancer	5.8e-05	0.000444	CcSEcCtD
Dapagliflozin—Pollakiuria—Doxorubicin—prostate cancer	5.75e-05	0.00044	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	5.68e-05	0.000435	CcSEcCtD
Dapagliflozin—Oedema—Docetaxel—prostate cancer	5.67e-05	0.000434	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Docetaxel—prostate cancer	5.67e-05	0.000434	CcSEcCtD
Dapagliflozin—Discomfort—Capecitabine—prostate cancer	5.66e-05	0.000433	CcSEcCtD
Dapagliflozin—Infection—Docetaxel—prostate cancer	5.63e-05	0.000431	CcSEcCtD
Dapagliflozin—Rash—Estradiol—prostate cancer	5.55e-05	0.000425	CcSEcCtD
Dapagliflozin—Infestation—Doxorubicin—prostate cancer	5.55e-05	0.000425	CcSEcCtD
Dapagliflozin—Infestation NOS—Doxorubicin—prostate cancer	5.55e-05	0.000425	CcSEcCtD
Dapagliflozin—Dermatitis—Estradiol—prostate cancer	5.54e-05	0.000424	CcSEcCtD
Dapagliflozin—Headache—Estradiol—prostate cancer	5.51e-05	0.000422	CcSEcCtD
Dapagliflozin—Skin disorder—Docetaxel—prostate cancer	5.5e-05	0.000421	CcSEcCtD
Dapagliflozin—Oedema—Capecitabine—prostate cancer	5.49e-05	0.00042	CcSEcCtD
Dapagliflozin—Angioedema—Prednisone—prostate cancer	5.47e-05	0.000419	CcSEcCtD
Dapagliflozin—Renal failure—Doxorubicin—prostate cancer	5.45e-05	0.000417	CcSEcCtD
Dapagliflozin—Infection—Capecitabine—prostate cancer	5.45e-05	0.000417	CcSEcCtD
Dapagliflozin—Urticaria—Etoposide—prostate cancer	5.42e-05	0.000415	CcSEcCtD
Dapagliflozin—Body temperature increased—Etoposide—prostate cancer	5.39e-05	0.000413	CcSEcCtD
Dapagliflozin—Urinary tract infection—Doxorubicin—prostate cancer	5.39e-05	0.000413	CcSEcCtD
Dapagliflozin—Skin disorder—Capecitabine—prostate cancer	5.33e-05	0.000408	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Epirubicin—prostate cancer	5.31e-05	0.000407	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Capecitabine—prostate cancer	5.3e-05	0.000406	CcSEcCtD
Dapagliflozin—Hypotension—Docetaxel—prostate cancer	5.3e-05	0.000405	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Epirubicin—prostate cancer	5.29e-05	0.000405	CcSEcCtD
Dapagliflozin—Urethral disorder—Epirubicin—prostate cancer	5.27e-05	0.000404	CcSEcCtD
Dapagliflozin—Nausea—Estradiol—prostate cancer	5.23e-05	0.0004	CcSEcCtD
Dapagliflozin—Hypertension—Prednisone—prostate cancer	5.17e-05	0.000396	CcSEcCtD
Dapagliflozin—Rash—Mitoxantrone—prostate cancer	5.17e-05	0.000396	CcSEcCtD
Dapagliflozin—Dermatitis—Mitoxantrone—prostate cancer	5.16e-05	0.000395	CcSEcCtD
Dapagliflozin—Headache—Mitoxantrone—prostate cancer	5.14e-05	0.000393	CcSEcCtD
Dapagliflozin—Hypotension—Capecitabine—prostate cancer	5.13e-05	0.000393	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	5.06e-05	0.000388	CcSEcCtD
Dapagliflozin—Discomfort—Prednisone—prostate cancer	5.04e-05	0.000386	CcSEcCtD
Dapagliflozin—Hypersensitivity—Etoposide—prostate cancer	5.02e-05	0.000385	CcSEcCtD
Dapagliflozin—Urinary tract disorder—Doxorubicin—prostate cancer	4.92e-05	0.000376	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Docetaxel—prostate cancer	4.89e-05	0.000375	CcSEcCtD
Dapagliflozin—Connective tissue disorder—Doxorubicin—prostate cancer	4.89e-05	0.000375	CcSEcCtD
Dapagliflozin—Oedema—Prednisone—prostate cancer	4.89e-05	0.000374	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Prednisone—prostate cancer	4.89e-05	0.000374	CcSEcCtD
Dapagliflozin—Urethral disorder—Doxorubicin—prostate cancer	4.88e-05	0.000374	CcSEcCtD
Dapagliflozin—Nausea—Mitoxantrone—prostate cancer	4.87e-05	0.000373	CcSEcCtD
Dapagliflozin—Infection—Prednisone—prostate cancer	4.86e-05	0.000372	CcSEcCtD
Dapagliflozin—Constipation—Docetaxel—prostate cancer	4.85e-05	0.000371	CcSEcCtD
Dapagliflozin—Skin disorder—Prednisone—prostate cancer	4.75e-05	0.000363	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Capecitabine—prostate cancer	4.74e-05	0.000363	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Prednisone—prostate cancer	4.73e-05	0.000362	CcSEcCtD
Dapagliflozin—Constipation—Capecitabine—prostate cancer	4.69e-05	0.000359	CcSEcCtD
Dapagliflozin—Malnutrition—Epirubicin—prostate cancer	4.68e-05	0.000359	CcSEcCtD
Dapagliflozin—Back pain—Epirubicin—prostate cancer	4.53e-05	0.000347	CcSEcCtD
Dapagliflozin—Dizziness—Etoposide—prostate cancer	4.51e-05	0.000345	CcSEcCtD
Dapagliflozin—Body temperature increased—Docetaxel—prostate cancer	4.48e-05	0.000343	CcSEcCtD
Dapagliflozin—Urticaria—Capecitabine—prostate cancer	4.36e-05	0.000334	CcSEcCtD
Dapagliflozin—Body temperature increased—Capecitabine—prostate cancer	4.34e-05	0.000332	CcSEcCtD
Dapagliflozin—Malnutrition—Doxorubicin—prostate cancer	4.33e-05	0.000332	CcSEcCtD
Dapagliflozin—Rash—Etoposide—prostate cancer	4.3e-05	0.000329	CcSEcCtD
Dapagliflozin—Dermatitis—Etoposide—prostate cancer	4.3e-05	0.000329	CcSEcCtD
Dapagliflozin—Headache—Etoposide—prostate cancer	4.27e-05	0.000327	CcSEcCtD
Dapagliflozin—Back pain—Doxorubicin—prostate cancer	4.19e-05	0.000321	CcSEcCtD
Dapagliflozin—Constipation—Prednisone—prostate cancer	4.18e-05	0.00032	CcSEcCtD
Dapagliflozin—Hypersensitivity—Docetaxel—prostate cancer	4.18e-05	0.00032	CcSEcCtD
Dapagliflozin—Nausea—Etoposide—prostate cancer	4.05e-05	0.00031	CcSEcCtD
Dapagliflozin—Hypertension—Epirubicin—prostate cancer	4.04e-05	0.00031	CcSEcCtD
Dapagliflozin—Hypersensitivity—Capecitabine—prostate cancer	4.04e-05	0.000309	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	3.96e-05	0.000303	CcSEcCtD
Dapagliflozin—Discomfort—Epirubicin—prostate cancer	3.94e-05	0.000302	CcSEcCtD
Dapagliflozin—Urticaria—Prednisone—prostate cancer	3.88e-05	0.000297	CcSEcCtD
Dapagliflozin—Body temperature increased—Prednisone—prostate cancer	3.86e-05	0.000296	CcSEcCtD
Dapagliflozin—Oedema—Epirubicin—prostate cancer	3.82e-05	0.000293	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Epirubicin—prostate cancer	3.82e-05	0.000293	CcSEcCtD
Dapagliflozin—Infection—Epirubicin—prostate cancer	3.8e-05	0.000291	CcSEcCtD
Dapagliflozin—Dizziness—Docetaxel—prostate cancer	3.75e-05	0.000287	CcSEcCtD
Dapagliflozin—Hypertension—Doxorubicin—prostate cancer	3.74e-05	0.000286	CcSEcCtD
Dapagliflozin—Skin disorder—Epirubicin—prostate cancer	3.71e-05	0.000284	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Epirubicin—prostate cancer	3.7e-05	0.000283	CcSEcCtD
Dapagliflozin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	3.66e-05	0.000281	CcSEcCtD
Dapagliflozin—Discomfort—Doxorubicin—prostate cancer	3.65e-05	0.000279	CcSEcCtD
Dapagliflozin—Dizziness—Capecitabine—prostate cancer	3.63e-05	0.000278	CcSEcCtD
Dapagliflozin—Hypersensitivity—Prednisone—prostate cancer	3.6e-05	0.000276	CcSEcCtD
Dapagliflozin—Rash—Docetaxel—prostate cancer	3.57e-05	0.000274	CcSEcCtD
Dapagliflozin—Hypotension—Epirubicin—prostate cancer	3.57e-05	0.000273	CcSEcCtD
Dapagliflozin—Dermatitis—Docetaxel—prostate cancer	3.57e-05	0.000273	CcSEcCtD
Dapagliflozin—Headache—Docetaxel—prostate cancer	3.55e-05	0.000272	CcSEcCtD
Dapagliflozin—Oedema—Doxorubicin—prostate cancer	3.54e-05	0.000271	CcSEcCtD
Dapagliflozin—Anaphylactic shock—Doxorubicin—prostate cancer	3.54e-05	0.000271	CcSEcCtD
Dapagliflozin—Infection—Doxorubicin—prostate cancer	3.51e-05	0.000269	CcSEcCtD
Dapagliflozin—Rash—Capecitabine—prostate cancer	3.46e-05	0.000265	CcSEcCtD
Dapagliflozin—Dermatitis—Capecitabine—prostate cancer	3.46e-05	0.000265	CcSEcCtD
Dapagliflozin—Headache—Capecitabine—prostate cancer	3.44e-05	0.000263	CcSEcCtD
Dapagliflozin—Skin disorder—Doxorubicin—prostate cancer	3.44e-05	0.000263	CcSEcCtD
Dapagliflozin—Hyperhidrosis—Doxorubicin—prostate cancer	3.42e-05	0.000262	CcSEcCtD
Dapagliflozin—Nausea—Docetaxel—prostate cancer	3.37e-05	0.000258	CcSEcCtD
Dapagliflozin—Hypotension—Doxorubicin—prostate cancer	3.31e-05	0.000253	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Epirubicin—prostate cancer	3.3e-05	0.000253	CcSEcCtD
Dapagliflozin—Constipation—Epirubicin—prostate cancer	3.27e-05	0.00025	CcSEcCtD
Dapagliflozin—Nausea—Capecitabine—prostate cancer	3.26e-05	0.00025	CcSEcCtD
Dapagliflozin—Dizziness—Prednisone—prostate cancer	3.23e-05	0.000247	CcSEcCtD
Dapagliflozin—Rash—Prednisone—prostate cancer	3.08e-05	0.000236	CcSEcCtD
Dapagliflozin—Dermatitis—Prednisone—prostate cancer	3.08e-05	0.000236	CcSEcCtD
Dapagliflozin—Headache—Prednisone—prostate cancer	3.06e-05	0.000234	CcSEcCtD
Dapagliflozin—Gastrointestinal disorder—Doxorubicin—prostate cancer	3.05e-05	0.000234	CcSEcCtD
Dapagliflozin—Urticaria—Epirubicin—prostate cancer	3.04e-05	0.000232	CcSEcCtD
Dapagliflozin—Constipation—Doxorubicin—prostate cancer	3.02e-05	0.000232	CcSEcCtD
Dapagliflozin—Body temperature increased—Epirubicin—prostate cancer	3.02e-05	0.000231	CcSEcCtD
Dapagliflozin—Nausea—Prednisone—prostate cancer	2.9e-05	0.000222	CcSEcCtD
Dapagliflozin—Hypersensitivity—Epirubicin—prostate cancer	2.82e-05	0.000216	CcSEcCtD
Dapagliflozin—Urticaria—Doxorubicin—prostate cancer	2.81e-05	0.000215	CcSEcCtD
Dapagliflozin—Body temperature increased—Doxorubicin—prostate cancer	2.8e-05	0.000214	CcSEcCtD
Dapagliflozin—Hypersensitivity—Doxorubicin—prostate cancer	2.61e-05	0.000199	CcSEcCtD
Dapagliflozin—Dizziness—Epirubicin—prostate cancer	2.53e-05	0.000194	CcSEcCtD
Dapagliflozin—Rash—Epirubicin—prostate cancer	2.41e-05	0.000185	CcSEcCtD
Dapagliflozin—Dermatitis—Epirubicin—prostate cancer	2.41e-05	0.000184	CcSEcCtD
Dapagliflozin—Headache—Epirubicin—prostate cancer	2.39e-05	0.000183	CcSEcCtD
Dapagliflozin—Dizziness—Doxorubicin—prostate cancer	2.34e-05	0.000179	CcSEcCtD
Dapagliflozin—Nausea—Epirubicin—prostate cancer	2.27e-05	0.000174	CcSEcCtD
Dapagliflozin—Rash—Doxorubicin—prostate cancer	2.23e-05	0.000171	CcSEcCtD
Dapagliflozin—Dermatitis—Doxorubicin—prostate cancer	2.23e-05	0.000171	CcSEcCtD
Dapagliflozin—Headache—Doxorubicin—prostate cancer	2.22e-05	0.00017	CcSEcCtD
Dapagliflozin—Nausea—Doxorubicin—prostate cancer	2.1e-05	0.000161	CcSEcCtD
Dapagliflozin—CYP3A4—Metabolism—GSTA4—prostate cancer	1.71e-06	1.32e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ITPR1—prostate cancer	1.71e-06	1.32e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NCOA2—prostate cancer	1.7e-06	1.31e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	1.7e-06	1.31e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NCOA2—prostate cancer	1.69e-06	1.3e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP2E1—prostate cancer	1.68e-06	1.3e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PTEN—prostate cancer	1.68e-06	1.29e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.68e-06	1.29e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTA2—prostate cancer	1.67e-06	1.28e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—NQO1—prostate cancer	1.67e-06	1.28e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—HPGDS—prostate cancer	1.65e-06	1.27e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ABCG5—prostate cancer	1.65e-06	1.27e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SULT1A1—prostate cancer	1.65e-06	1.27e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—TH—prostate cancer	1.64e-06	1.26e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP2C19—prostate cancer	1.64e-06	1.26e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—SLC5A5—prostate cancer	1.63e-06	1.25e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP3A4—prostate cancer	1.62e-06	1.25e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—TYMS—prostate cancer	1.62e-06	1.24e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—SLC5A5—prostate cancer	1.61e-06	1.24e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTA1—prostate cancer	1.61e-06	1.24e-05	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—EP300—prostate cancer	1.61e-06	1.23e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTT1—prostate cancer	1.6e-06	1.23e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ACHE—prostate cancer	1.6e-06	1.23e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—GSTM1—prostate cancer	1.6e-06	1.23e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP1B1—prostate cancer	1.6e-06	1.23e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CG—prostate cancer	1.59e-06	1.23e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NAT2—prostate cancer	1.59e-06	1.22e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTO1—prostate cancer	1.59e-06	1.22e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—HSD3B2—prostate cancer	1.59e-06	1.22e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP2E1—prostate cancer	1.59e-06	1.22e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CB—prostate cancer	1.58e-06	1.22e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP2A6—prostate cancer	1.58e-06	1.22e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	1.58e-06	1.21e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP2E1—prostate cancer	1.57e-06	1.21e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NQO1—prostate cancer	1.57e-06	1.21e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—LPL—prostate cancer	1.57e-06	1.21e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PTGS2—prostate cancer	1.57e-06	1.21e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NQO1—prostate cancer	1.56e-06	1.2e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—TH—prostate cancer	1.55e-06	1.19e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GGT1—prostate cancer	1.55e-06	1.19e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—AKR1C3—prostate cancer	1.54e-06	1.18e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—TH—prostate cancer	1.53e-06	1.18e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP3A4—prostate cancer	1.53e-06	1.18e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PRKACB—prostate cancer	1.53e-06	1.18e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PLCB2—prostate cancer	1.53e-06	1.17e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP2C18—prostate cancer	1.53e-06	1.17e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—LRP2—prostate cancer	1.53e-06	1.17e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.52e-06	1.17e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—NCOA1—prostate cancer	1.52e-06	1.17e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP3A4—prostate cancer	1.52e-06	1.17e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP17A1—prostate cancer	1.51e-06	1.16e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.51e-06	1.16e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—INS—prostate cancer	1.51e-06	1.16e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP1B1—prostate cancer	1.5e-06	1.16e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—ERCC2—prostate cancer	1.5e-06	1.16e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP19A1—prostate cancer	1.5e-06	1.15e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—P4HB—prostate cancer	1.5e-06	1.15e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	1.49e-06	1.15e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP1B1—prostate cancer	1.49e-06	1.15e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—CREBBP—prostate cancer	1.48e-06	1.14e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GGT1—prostate cancer	1.46e-06	1.12e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SLC22A1—prostate cancer	1.46e-06	1.12e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—RXRA—prostate cancer	1.45e-06	1.11e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GGT1—prostate cancer	1.44e-06	1.11e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NCOA2—prostate cancer	1.44e-06	1.11e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NCOA1—prostate cancer	1.44e-06	1.1e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NCOA1—prostate cancer	1.42e-06	1.09e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SULT2A1—prostate cancer	1.42e-06	1.09e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP19A1—prostate cancer	1.41e-06	1.09e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—MTHFR—prostate cancer	1.41e-06	1.09e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP19A1—prostate cancer	1.4e-06	1.08e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CD—prostate cancer	1.4e-06	1.08e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—MED12—prostate cancer	1.4e-06	1.07e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—COMT—prostate cancer	1.4e-06	1.07e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTP1—prostate cancer	1.39e-06	1.07e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PPARA—prostate cancer	1.39e-06	1.07e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GNG5—prostate cancer	1.39e-06	1.07e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—SLC5A5—prostate cancer	1.38e-06	1.06e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PTEN—prostate cancer	1.37e-06	1.05e-05	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ITPR1—prostate cancer	1.37e-06	1.05e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—RXRA—prostate cancer	1.37e-06	1.05e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—RXRA—prostate cancer	1.35e-06	1.04e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP2E1—prostate cancer	1.34e-06	1.03e-05	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NCOA3—prostate cancer	1.33e-06	1.03e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NQO1—prostate cancer	1.33e-06	1.02e-05	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—NOS3—prostate cancer	1.32e-06	1.02e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.32e-06	1.01e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—COMT—prostate cancer	1.32e-06	1.01e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—TH—prostate cancer	1.31e-06	1.01e-05	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTP1—prostate cancer	1.31e-06	1.01e-05	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—EP300—prostate cancer	1.3e-06	1e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—COMT—prostate cancer	1.3e-06	1e-05	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CAV1—prostate cancer	1.3e-06	1e-05	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.3e-06	1e-05	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTP1—prostate cancer	1.3e-06	9.98e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP3A4—prostate cancer	1.3e-06	9.97e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—TYMS—prostate cancer	1.29e-06	9.93e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.29e-06	9.92e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ITPR1—prostate cancer	1.29e-06	9.91e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ITPR1—prostate cancer	1.28e-06	9.82e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—GSTM1—prostate cancer	1.28e-06	9.82e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP1B1—prostate cancer	1.27e-06	9.8e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—HPGDS—prostate cancer	1.27e-06	9.79e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP2C19—prostate cancer	1.27e-06	9.73e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.26e-06	9.66e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—LPL—prostate cancer	1.25e-06	9.64e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.24e-06	9.57e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTT1—prostate cancer	1.23e-06	9.5e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ACHE—prostate cancer	1.23e-06	9.5e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GGT1—prostate cancer	1.23e-06	9.5e-06	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CB—prostate cancer	1.22e-06	9.39e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP2A6—prostate cancer	1.22e-06	9.39e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—TYMS—prostate cancer	1.22e-06	9.36e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NCOA1—prostate cancer	1.22e-06	9.35e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CYP1A1—prostate cancer	1.21e-06	9.31e-06	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PTGS2—prostate cancer	1.21e-06	9.3e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—TYMS—prostate cancer	1.21e-06	9.28e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—GSTM1—prostate cancer	1.2e-06	9.25e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—ERCC2—prostate cancer	1.2e-06	9.23e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP19A1—prostate cancer	1.2e-06	9.22e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—GSTM1—prostate cancer	1.19e-06	9.17e-06	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—PIK3CA—prostate cancer	1.19e-06	9.14e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—AKR1C3—prostate cancer	1.19e-06	9.13e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CG—prostate cancer	1.19e-06	9.13e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PRKACB—prostate cancer	1.18e-06	9.08e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—LPL—prostate cancer	1.18e-06	9.08e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—LPL—prostate cancer	1.17e-06	9e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP17A1—prostate cancer	1.17e-06	8.99e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—RXRA—prostate cancer	1.16e-06	8.9e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CYP1A1—prostate cancer	1.14e-06	8.77e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—ERCC2—prostate cancer	1.13e-06	8.7e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CYP1A1—prostate cancer	1.13e-06	8.7e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—MTHFR—prostate cancer	1.13e-06	8.68e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.13e-06	8.65e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—INS—prostate cancer	1.12e-06	8.64e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—ERCC2—prostate cancer	1.12e-06	8.62e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—COMT—prostate cancer	1.11e-06	8.57e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NCOA2—prostate cancer	1.11e-06	8.57e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTP1—prostate cancer	1.11e-06	8.53e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PPARA—prostate cancer	1.11e-06	8.51e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—CREBBP—prostate cancer	1.1e-06	8.46e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ITPR1—prostate cancer	1.09e-06	8.39e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.07e-06	8.25e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—MTHFR—prostate cancer	1.06e-06	8.18e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—SLC5A5—prostate cancer	1.06e-06	8.17e-06	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PTEN—prostate cancer	1.05e-06	8.11e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—MTHFR—prostate cancer	1.05e-06	8.11e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CD—prostate cancer	1.04e-06	8.02e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PPARA—prostate cancer	1.04e-06	8.02e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CAV1—prostate cancer	1.04e-06	8e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP2E1—prostate cancer	1.04e-06	7.98e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PPARA—prostate cancer	1.03e-06	7.95e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—TYMS—prostate cancer	1.03e-06	7.93e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NQO1—prostate cancer	1.03e-06	7.89e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—GSTM1—prostate cancer	1.02e-06	7.84e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—TH—prostate cancer	1.01e-06	7.78e-06	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—EP300—prostate cancer	1.01e-06	7.74e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—LPL—prostate cancer	1e-06	7.69e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—NOS3—prostate cancer	9.85e-07	7.58e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP1B1—prostate cancer	9.84e-07	7.57e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CAV1—prostate cancer	9.81e-07	7.54e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CAV1—prostate cancer	9.72e-07	7.48e-06	CbGpPWpGaD
Dapagliflozin—UGT2B7—Metabolism—AKT1—prostate cancer	9.7e-07	7.46e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CYP1A1—prostate cancer	9.66e-07	7.43e-06	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—PIK3CA—prostate cancer	9.65e-07	7.42e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—ERCC2—prostate cancer	9.58e-07	7.37e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GGT1—prostate cancer	9.53e-07	7.33e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CG—prostate cancer	9.48e-07	7.29e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NCOA1—prostate cancer	9.39e-07	7.22e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	9.29e-07	7.14e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP19A1—prostate cancer	9.25e-07	7.11e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CB—prostate cancer	9.09e-07	6.99e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PTGS2—prostate cancer	9.01e-07	6.93e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—MTHFR—prostate cancer	9.01e-07	6.93e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—INS—prostate cancer	8.97e-07	6.9e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CG—prostate cancer	8.93e-07	6.87e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—RXRA—prostate cancer	8.93e-07	6.87e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CG—prostate cancer	8.86e-07	6.81e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PPARA—prostate cancer	8.84e-07	6.8e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—CREBBP—prostate cancer	8.79e-07	6.76e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—COMT—prostate cancer	8.6e-07	6.61e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTP1—prostate cancer	8.56e-07	6.58e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—INS—prostate cancer	8.46e-07	6.5e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ITPR1—prostate cancer	8.42e-07	6.48e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—INS—prostate cancer	8.38e-07	6.45e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CD—prostate cancer	8.33e-07	6.41e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CAV1—prostate cancer	8.31e-07	6.39e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—CREBBP—prostate cancer	8.28e-07	6.37e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—CREBBP—prostate cancer	8.21e-07	6.31e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—TYMS—prostate cancer	7.96e-07	6.12e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	7.94e-07	6.1e-06	CbGpPWpGaD
Dapagliflozin—UGT1A9—Metabolism—AKT1—prostate cancer	7.89e-07	6.06e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—NOS3—prostate cancer	7.87e-07	6.05e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—GSTM1—prostate cancer	7.87e-07	6.05e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PTEN—prostate cancer	7.86e-07	6.04e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CD—prostate cancer	7.85e-07	6.04e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CD—prostate cancer	7.79e-07	5.99e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—LPL—prostate cancer	7.72e-07	5.94e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CG—prostate cancer	7.57e-07	5.82e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—EP300—prostate cancer	7.49e-07	5.76e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CYP1A1—prostate cancer	7.46e-07	5.73e-06	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—PIK3CA—prostate cancer	7.44e-07	5.72e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—NOS3—prostate cancer	7.42e-07	5.7e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—ERCC2—prostate cancer	7.4e-07	5.69e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—NOS3—prostate cancer	7.35e-07	5.65e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CB—prostate cancer	7.26e-07	5.59e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PTGS2—prostate cancer	7.2e-07	5.54e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—INS—prostate cancer	7.16e-07	5.51e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—CREBBP—prostate cancer	7.02e-07	5.4e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—MTHFR—prostate cancer	6.95e-07	5.35e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CB—prostate cancer	6.85e-07	5.26e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PPARA—prostate cancer	6.82e-07	5.24e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CB—prostate cancer	6.79e-07	5.22e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PTGS2—prostate cancer	6.78e-07	5.22e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PTGS2—prostate cancer	6.72e-07	5.17e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CD—prostate cancer	6.65e-07	5.12e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CAV1—prostate cancer	6.41e-07	4.93e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—NOS3—prostate cancer	6.28e-07	4.83e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PTEN—prostate cancer	6.28e-07	4.83e-06	CbGpPWpGaD
Dapagliflozin—CYP2A6—Metabolism—AKT1—prostate cancer	6.08e-07	4.67e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—EP300—prostate cancer	5.99e-07	4.6e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PTEN—prostate cancer	5.92e-07	4.55e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PTEN—prostate cancer	5.86e-07	4.51e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CG—prostate cancer	5.84e-07	4.49e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CB—prostate cancer	5.8e-07	4.46e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PTGS2—prostate cancer	5.75e-07	4.42e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—EP300—prostate cancer	5.64e-07	4.34e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—EP300—prostate cancer	5.59e-07	4.3e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—PIK3CA—prostate cancer	5.54e-07	4.26e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—INS—prostate cancer	5.53e-07	4.25e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—CREBBP—prostate cancer	5.42e-07	4.16e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CD—prostate cancer	5.13e-07	3.95e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PTEN—prostate cancer	5.01e-07	3.85e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—NOS3—prostate cancer	4.85e-07	3.73e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—EP300—prostate cancer	4.78e-07	3.68e-06	CbGpPWpGaD
Dapagliflozin—CYP1A1—Metabolism—AKT1—prostate cancer	4.53e-07	3.48e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CB—prostate cancer	4.48e-07	3.44e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PTGS2—prostate cancer	4.43e-07	3.41e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—PIK3CA—prostate cancer	4.43e-07	3.41e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—PIK3CA—prostate cancer	4.17e-07	3.21e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—PIK3CA—prostate cancer	4.14e-07	3.18e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PTEN—prostate cancer	3.87e-07	2.97e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—EP300—prostate cancer	3.69e-07	2.84e-06	CbGpPWpGaD
Dapagliflozin—ABCB1—Metabolism—AKT1—prostate cancer	3.62e-07	2.78e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—PIK3CA—prostate cancer	3.54e-07	2.72e-06	CbGpPWpGaD
Dapagliflozin—CYP2D6—Metabolism—AKT1—prostate cancer	3.41e-07	2.62e-06	CbGpPWpGaD
Dapagliflozin—CYP2C9—Metabolism—AKT1—prostate cancer	3.38e-07	2.6e-06	CbGpPWpGaD
Dapagliflozin—CYP1A2—Metabolism—AKT1—prostate cancer	2.89e-07	2.22e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—PIK3CA—prostate cancer	2.73e-07	2.1e-06	CbGpPWpGaD
Dapagliflozin—CYP3A4—Metabolism—AKT1—prostate cancer	2.23e-07	1.71e-06	CbGpPWpGaD
